Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$1.37B-96.7%-$1.13B-88.5%-$960.98M-69.5%-$812.06M-56.4%-$697.51M-44.0%
$8.43M+27.3%$7.78M+20.2%$7.25M+19.1%$6.79M+17.2%$6.63M+23.0%
$180.6M+105%$118.39M+49.5%$107.13M+30.4%$97.13M+29.4%$88.07M+29.0%
-$1.06B-78.8%-$897.74M-61.0%-$761.79M-41.1%-$684.9M-34.4%-$591.31M-31.8%
$14.26M+37.0%$15.99M+55.1%$15.29M+34.1%$15.46M+48.4%$10.41M+13.9%
$306.62M$118.06M-$349.73M-$396.05M
$860.99M-10.3%$623.12M-35.1%$1.13B+22.3%$1.21B+42.4%$959.48M+5.9%
-$1.07B-78.1%-$913.73M-60.9%-$777.08M-41.0%-$700.36M-34.6%-$601.72M-31.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Revolution Medicines, Inc. generate?
Revolution Medicines, Inc. (RVMD) generated -$1.1B in operating cash flow over the trailing twelve months.
What is Revolution Medicines, Inc.'s free cash flow?
After $14.3M of capital expenditures, Revolution Medicines, Inc.'s free cash flow was -$1.1B over the trailing twelve months, down 78.1% year over year.
Where does Revolution Medicines, Inc.'s cash flow data come from?
Every line is extracted from Revolution Medicines, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.